[英文調查報告書] 癌症治療用抗血管生成劑研發：競爭動向

Abstract

Executive Summary

There is a plethora of new anti-angiogenic drugs in development. The potential to block tumor growth and metastases by angiogenesis inhibition represents an intriguing therapeutic strategy for the treatment of cancer and never before have we seen as many anti-angiogenic drugs in clinical trials.

This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you. First, BioSeeker has surveyed anti-angiogenic drugs in oncology and identified 108 drug targets, belonging to 123drugs. This report, Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new anti-angiogenic drugs in oncology.

In the report, BioSeeker reports on 88 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 123 anti-angiogenic drugs designed for the treatment of 44 different cancer indications. The highest degree of distinctiveness among anti-angiogenic drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of anti-angiogenic drugs. No less than 162 protein-protein interactions were recognized among and between 86 of the 108 included anti-angiogenic drug targets.

Why You Should Own Your Own Copy of this Report:

230+ pages, with almost a hundred different tables and figures. Includes more than 1,500 active links to related resources on the Internet
123 anti-angiogenic drugs, under development by 90 investigators, are included, covering more than 361 developmental projects in cancer
108 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other anti-angiogenic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
Unique 231 drug-protein target interactome analysis
Unique drug target combination breakdown into 44 different cancer types
Covers 88 unique drug target combinations of anti-angiogenic drugs
162 protein-protein interactions among and between anti-angiogenic drug targets
Pathway grouping of anti-angiogenic drug targets
Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
Who are working on sequels to blockbuster drugs
Locate white-spots in the competitive landscape, giving you little or no competition

In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 Table of Contents

4.1 List of Figures
4.2 List of Tables

5 How to Use this Report

6 Anti-Angiogenic Drug Compound Types and Sub-cellular Localizations of Targets

7 The Cancer Genome Project and Angiogenesis Drug Targets

7.1 Anti-Angiogenic Drug Targets Present in the Cancer Gene Census and in the Catalogue Somatic Mutations in Cancer

8 Protein Expression Profiles of Anti-Angiogenic Drug Targets in Human

8.1 Expression in Normal Tissues and Cancer Tissues
8.2 Expression in Human Cancer Cell Lines and Primary Cells

9 Pathway Analysis of Anti-Angiogenic Drugs

10 Protein-Protein Interactions Among Identified Anti-Angiogenic Drug Targets

11 Available Biological Structure Data on Anti-Angiogenic Drug Targets

12 Drug Target Profiles of Anti-angiogenesis Drug Targets in Oncology

12.1.1 Carboxy-Lyase Activity
12.1.2 Catalytic Activity
12.1.3 Cell Adhesion Molecule Activity
12.1.4 Chaperone Activity
12.1.5 Cofactor Binding
12.1.6 Cysteine-Type Peptidase Activity
12.1.7 Cytokine Activity
12.1.8 DNA Topoisomerase Activity
12.1.9 DNA-Directed DNA Polymerase Activity
12.1.10 Extracellular Matrix Structural Constituent
12.1.11 G-Protein Coupled Receptor Activity
12.1.12 Growth Factor Activity
12.1.13 GTPase Activity
12.1.14 Hydrolase Activity
12.1.15 Kinase Activity
12.1.16 Lipid Kinase Activity
12.1.17 Metallopeptidase Activity
12.1.18 Molecular Function Unknown
12.1.19 Motor Activity
12.1.20 Peptidase Activity
12.1.21 Protease Inhibitor Activity
12.1.22 Protein Serine/Threonine Kinase Activity
12.1.23 Protein-Tyrosine Kinase Activity
12.1.24 Receptor Activity
12.1.25 Receptor Binding
12.1.26 Serine-Type Peptidase Activity
12.1.27 Structural Constituent of Cytoskeleton
12.1.28 Superoxide Dismutase Activity
12.1.29 Transcription Factor Activity
12.1.30 Transcription Regulator Activity
12.1.31 Translation Regulator Activity
12.1.32 Transmembrane Receptor Activity
12.1.33 Transmembrane Receptor Protein Tyrosine Kinase Activity
12.1.34 Transporter Activity

13 The Drug-Protein Interactome of Anti-Angiogenic Drugs

14 The Progression and Maturity of Anti-Angiogenic Drug Target Combinations

14.1 Target Profiles of Anti-Angiogenic Drugs on the Market
14.2 New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
14.3 New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
14.4 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
14.5 New Anti-Angiogenic Drug Target Combinations in Preclinical Development
14.6 Development Profiles of All Identified Anti-Angiogenic Drug Target Combinations

15 Anti-Angiogenic Drug Target Mix by Cancer Indication

15.1 Adrenal Cancer
15.2 Biliary Cancer
15.3 Bladder Cancer
15.4 Bone Cancer
15.5 Brain Cancer
15.6 Breast Cancer
15.7 Carcinoid Tumor
15.8 Cervical Cancer
15.9 Chemotherapy-Induced Infection
15.10 Colorectal Cancer
15.11 Endometrial Cancer
15.12 Fallopian Tube Cancer
15.13 Gastrointestinal Cancer
- 15.13.1 Gastrointestinal Stomach Cancer
- 15.13.2 Gastrointestinal Stromal Cancer
15.14 Head and Neck Cancer
15.15 Leukemia
- 15.15.1 Acute Lymphocytic Leukemia
- 15.15.2 Acute Myelogenous Leukemia
- 15.15.3 Chronic Lymphocytic Leukemia
- 15.15.4 Chronic Myelogenous Leukemia
15.16 Liver Cancer
15.17 Lung Cancer
- 15.17.1 Non-Small Cell Lung Cancer
- 15.17.2 Small Cell Lung Cancer
15.18 Lymphoma
- 15.18.1 B-Cell Lymphoma
- 15.18.2 Hodgkin' s Lymphoma
- 15.18.3 Non-Hodgkin' s Lymphoma
15.19 Melanoma
15.20 Mesothelioma
15.21 Myelodysplastic Syndrome
15.22 Myeloma
15.23 Nasopharyngeal Cancer
15.24 Oesophageal Cancer
15.25 Ovarian Cancer
15.26 Pancreatic Cancer
15.27 Peritoneal Cancer
15.28 Prostate Cancer
15.29 Renal Cancer
15.30 Sarcoma
- 15.30.1 Leiomyo Sarcoma
15.31 Squamous Cell Cancer
15.32 Thyroid Cancer

16 Anti-Angiogenic Drugs and Their Targets by Companies

16.1 Australia
16.2 Austria
16.3 Belgium
16.4 Canada
16.5 China
16.6 Denmark
16.7 France
16.8 Germany
16.9 Israel
16.10 Japan
16.11 Netherlands
16.12 South Korea
16.13 Spain
16.14 Sweden
16.15 Switzerland
16.16 United Kingdom
16.17 USA

17 Disclaimer

18 Drug Index

19 Company Index

List of Figures

Figure 1: Distribution of Compound Types Among Anti-Angiogenic Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
Figure 4: The Drug-Protein Interactome of Anti-Angiogenic Drugs
Figure 5: Direct Head-to-Head Targeting Interactome of Anti-Angiogenic Drugs

List of Tables

Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
Table 2: Drug Targets of Anti-Angiogenic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Anti-Angiogenic Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of the Anti-Angiogenic Drug Targets
Table 7: Pathway Profile According to KEGG of the Anti-Angiogenic Drug Targets
Table 8: Anti-Angiogenic Drugs Targeting Major Singaling Pathways
Table 9: Protein-Protein Interactions Among Anti-Angiogenic Drug Targets
Table 10: Number of Available Biological Structures on Anti-Angiogenic Drug Targets
Table 11: Overview of Drug Target Profile Themes
Table 12: Drug-Protein Clusters in the Anti-Angiogenic Interactome
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by Developmental Stage
Table 14: Target Profiles of Anti-Angiogenic Drugs on the Market
Table 15: New Anti-Angiogenic Drug Target Combinations in Phase III Clinical Development
Table 16: New Anti-Angiogenic Drug Target Combinations in Phase II Clinical Development
Table 17 New Anti-Angiogenic Drug Target Combinations Phase I Clinical Development
Table 18: New Anti-Angiogenic Drug Target Combinations in Preclinical Development
Table 19: The Progression, Maturity and Comptitive Comparison of Anti-Angiogenic Drug Target Mixes in Development
Table 20: Number of Unique Anti-angiogenic Drug Target Mixes Reported by Cancer Indication
Table 21: The Competitive Situation on Bevacizumab (Avastin)
Table 22: Anti-angiogenic Drug Target Mix for the Treatment of Adrenal Cancer According to the Compound Type and Developmental Stage of Drug
Table 23: Anti-angiogenic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
Table 24: Anti-angiogenic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
Table 25: Anti-angiogenic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
Table 26: Anti-angiogenic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
Table 27: Anti-angiogenic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
Table 28: Anti-angiogenic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
Table 29: Anti-angiogenic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type and Developmental Stage of Drug
Table 30: Anti-angiogenic Drug Target Mix for the Treatment of Chemotherapy-induced Infection According to the Compound Type and Developmental Stage of Drug
Table 31: Anti-angiogenic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
Table 32: Anti-angiogenic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
Table 33: Anti-angiogenic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
Table 34: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Cancer (General) According to the Compound Type and Developmental Stage of Drug
Table 35: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
Table 36: Anti-angiogenic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
Table 37: Anti-angiogenic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
Table 38: Anti-angiogenic Drug Target Mix for the Treatment of Leukemia (General) According to the Compound Type and Developmental Stage of Drug
Table 39: Anti-angiogenic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
Table 40: Anti-angiogenic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
Table 41: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
Table 42: Anti-angiogenic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia Cancer According to the Compound Type and Developmental Stage of Drug
Table 43: Anti-angiogenic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
Table 44: Anti-angiogenic Drug Target Mix for the Treatment of Lung Cancer (General) According to the Compound Type and Developmental Stage of Drug
Table 45: Anti-angiogenic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 46: Anti-angiogenic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
Table 47: Anti-angiogenic Drug Target Mix for the Treatment of Lymphoma (General) According to the Compound Type and Developmental Stage of Drug
Table 48: Anti-angiogenic Drug Target Mix for the Treatment of B-Cell Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 49: Anti-angiogenic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 50: Anti-angiogenic Drug Target Mix for the Treatment of Non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
Table 51: Anti-angiogenic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
Table 52: Anti-angiogenic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
Table 53: Anti-angiogenic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
Table 54: Anti-angiogenic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
Table 55: Anti-angiogenic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
Table 56: Anti-angiogenic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
Table 57: Anti-angiogenic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
Table 58: Anti-angiogenic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
Table 59: Anti-angiogenic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
Table 60: Anti-angiogenic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
Table 61: Anti-angiogenic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
Table 62: Anti-angiogenic Drug Target Mix for the Treatment of Sarcoma (General) According to the Compound Type and Developmental Stage of Drug
Table 63: Anti-angiogenic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
Table 64: Anti-angiogenic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
Table 65: Anti-angiogenic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
Table 66: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Australia
Table 67: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Austria
Table 68: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Belgium
Table 69: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Canada
Table 70: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in China
Table 71: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Denmark
Table 72: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in France
Table 73; Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Germany
Table 74: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Israel
Table 75: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Japan
Table 76: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in the Netherlands
Table 77: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
Table 78: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in South Korea
Table 79: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Sweden
Table 80: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in Switzerland
Table 81: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in United Kingdom
Table 82: Anti-angiogenic drugs with Target Mix and Developmental Projects by Companies in USA